These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24928441)

  • 21. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques.
    Wierda RJ; Rietveld IM; van Eggermond MC; Belien JA; van Zwet EW; Lindeman JH; van den Elsen PJ
    Life Sci; 2015 May; 129():3-9. PubMed ID: 25445221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.
    Kogure M; Takawa M; Saloura V; Sone K; Piao L; Ueda K; Ibrahim R; Tsunoda T; Sugiyama M; Atomi Y; Nakamura Y; Hamamoto R
    Neoplasia; 2013 Nov; 15(11):1251-61. PubMed ID: 24339737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
    Ott HM; Graves AP; Pappalardi MB; Huddleston M; Halsey WS; Hughes AM; Groy A; Dul E; Jiang Y; Bai Y; Annan R; Verma SK; Knight SD; Kruger RG; Dhanak D; Schwartz B; Tummino PJ; Creasy CL; McCabe MT
    Mol Cancer Ther; 2014 Dec; 13(12):3062-73. PubMed ID: 25253781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
    Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
    PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
    Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
    Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.
    Gherardi S; Ripoche D; Mikaelian I; Chanal M; Teinturier R; Goehrig D; Cordier-Bussat M; Zhang CX; Hennino A; Bertolino P
    Biochim Biophys Acta Gene Regul Mech; 2017 Apr; 1860(4):427-437. PubMed ID: 28215965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival.
    Hou Z; Zhao W; Zhou J; Shen L; Zhan P; Xu C; Chang C; Bi H; Zou J; Yao X; Huang R; Yu L; Yan J
    Int J Biochem Cell Biol; 2014 Aug; 53():380-8. PubMed ID: 24927902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.
    Hemming S; Cakouros D; Isenmann S; Cooper L; Menicanin D; Zannettino A; Gronthos S
    Stem Cells; 2014 Mar; 32(3):802-15. PubMed ID: 24123378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
    Lv YF; Yan GN; Meng G; Zhang X; Guo QN
    Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
    Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G
    Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2 in normal hematopoiesis and hematological malignancies.
    Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
    Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
    Chinaranagari S; Sharma P; Chaudhary J
    Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
    Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
    Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
    Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
    Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
    Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
    Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
    Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.